259 related articles for article (PubMed ID: 31383341)
1. IL-1 blockers together with colchicine may be administered as first line therapy in familial Mediterranean fever with amyloidosis.
Tezcan ME
Med Hypotheses; 2019 Sep; 130():109269. PubMed ID: 31383341
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
3. [Nephrotic syndrome in familial Mediterranean fever--effect of colchicine therapy].
Højberg AS; Mertz H
Ugeskr Laeger; 1995 Jul; 157(28):4035-7. PubMed ID: 7645081
[TBL] [Abstract][Full Text] [Related]
4. Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis.
Sevillano ÁM; Hernandez E; Gonzalez E; Mateo I; Gutierrez E; Morales E; Praga M
Nefrologia; 2016; 36(1):63-6. PubMed ID: 26409501
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever.
Hamanoue S; Suwabe T; Hoshino J; Sumida K; Mise K; Hayami N; Sawa N; Takaichi K; Fujii T; Ohashi K; Yazaki M; Ikeda S; Ubara Y
Mod Rheumatol; 2016 Jul; 26(4):610-3. PubMed ID: 25619282
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever.
Ugurlu S; Ergezen B; Egeli BH; Selvi O; Ozdogan H
Rheumatology (Oxford); 2020 Dec; 59(12):3892-3899. PubMed ID: 32556219
[TBL] [Abstract][Full Text] [Related]
10. Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
Sozeri B; Kasapcopur O
Curr Med Chem; 2015; 22(16):1986-91. PubMed ID: 25760087
[TBL] [Abstract][Full Text] [Related]
11. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation.
Moser C; Pohl G; Haslinger I; Knapp S; Rowczenio D; Russel T; Lachmann HJ; Lang U; Kovarik J
Nephrol Dial Transplant; 2009 Feb; 24(2):676-8. PubMed ID: 19033248
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic approach to patients with familial Mediterranean fever-related amyloidosis resistant to colchicine.
Korkmaz C
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S104-7. PubMed ID: 23010471
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
15. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure.
Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G
Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121
[TBL] [Abstract][Full Text] [Related]
16. IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.
Kharouf F; Tsemach-Toren T; Ben-Chetrit E
Clin Exp Rheumatol; 2022 Sep; 40(8):1567-1574. PubMed ID: 36062765
[TBL] [Abstract][Full Text] [Related]
17. [Fever of unknown origin and colchicine-sensitive amyloidosis: familial Mediterranean fever?].
Schneider W; Wehmeier A
Dtsch Med Wochenschr; 1989 Jun; 114(24):951-4. PubMed ID: 2731480
[TBL] [Abstract][Full Text] [Related]
18. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever.
Livneh A; Zemer D; Siegal B; Laor A; Sohar E; Pras M
Nephron; 1992; 60(4):418-22. PubMed ID: 1584316
[TBL] [Abstract][Full Text] [Related]
19. Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report.
Peces R; Afonso S; Peces C; Nevado J; Selgas R
BMC Med Genet; 2017 Aug; 18(1):97. PubMed ID: 28859624
[TBL] [Abstract][Full Text] [Related]
20. Familial Mediterranean fever in childhood: a single-center experience.
Barut K; Sahin S; Adrovic A; Sinoplu AB; Yucel G; Pamuk G; Aydın AK; Dasdemir S; Turanlı ET; Buyru N; Kasapcopur O
Rheumatol Int; 2018 Jan; 38(1):67-74. PubMed ID: 28828621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
